MX2016014660A - Medios y metodos para el tratamiento de cmv. - Google Patents

Medios y metodos para el tratamiento de cmv.

Info

Publication number
MX2016014660A
MX2016014660A MX2016014660A MX2016014660A MX2016014660A MX 2016014660 A MX2016014660 A MX 2016014660A MX 2016014660 A MX2016014660 A MX 2016014660A MX 2016014660 A MX2016014660 A MX 2016014660A MX 2016014660 A MX2016014660 A MX 2016014660A
Authority
MX
Mexico
Prior art keywords
methods
cmv
pentameric
treating cmv
provides
Prior art date
Application number
MX2016014660A
Other languages
English (en)
Inventor
Wellnitz Sabine
John Corinne
Schaub Christian
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of MX2016014660A publication Critical patent/MX2016014660A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/245—Herpetoviridae, e.g. herpes simplex virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/14011—Baculoviridae
    • C12N2710/14041—Use of virus, viral particle or viral elements as a vector
    • C12N2710/14043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vectore
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16111—Cytomegalovirus, e.g. human herpesvirus 5
    • C12N2710/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16111—Cytomegalovirus, e.g. human herpesvirus 5
    • C12N2710/16151—Methods of production or purification of viral material

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Plant Pathology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

La presente invención se refiere al campo de la producción de proteínas recombinantes y la preparación de vacunas. En particular, la invención proporciona medios y métodos para la producción del complejo pentamérico gH/gL/UL128/UL130/UL131A de CMV. Más específicamente, la invención proporciona un complejo pentamérico gH/gL/UL128/UL130/UL131A de CMV producido en un sistema de baculovirus que puede ser utilizado como una vacuna contra el CMV.
MX2016014660A 2014-05-08 2015-05-08 Medios y metodos para el tratamiento de cmv. MX2016014660A (es)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
LU92449 2014-05-08
LU92450 2014-05-08
LU92452 2014-05-08
LU92451 2014-05-08
PCT/IB2015/053365 WO2015170287A1 (en) 2014-05-08 2015-05-08 Means and methods for treating cmv

Publications (1)

Publication Number Publication Date
MX2016014660A true MX2016014660A (es) 2017-02-28

Family

ID=53180768

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2016014660A MX2016014660A (es) 2014-05-08 2015-05-08 Medios y metodos para el tratamiento de cmv.

Country Status (16)

Country Link
US (1) US20150322115A1 (es)
EP (1) EP3139953A1 (es)
JP (1) JP2017515503A (es)
KR (1) KR20170002560A (es)
CN (1) CN106460010A (es)
AU (1) AU2015257330A1 (es)
BR (1) BR112016025792A2 (es)
CA (1) CA2947938A1 (es)
IL (1) IL248803A0 (es)
MX (1) MX2016014660A (es)
PE (1) PE20170301A1 (es)
PH (1) PH12016502220A1 (es)
RU (1) RU2016147987A (es)
SG (1) SG11201608977UA (es)
TW (1) TW201609792A (es)
WO (1) WO2015170287A1 (es)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015048744A2 (en) 2013-09-30 2015-04-02 Moderna Therapeutics, Inc. Polynucleotides encoding immune modulating polypeptides
WO2017070613A1 (en) 2015-10-22 2017-04-27 Modernatx, Inc. Human cytomegalovirus vaccine
EP3445393A4 (en) * 2016-04-20 2020-08-05 Merck Sharp & Dohme Corp. CMV NEUTRALIZATION ANTIGEN BINDING PROTEINS
AU2017345766A1 (en) 2016-10-21 2019-05-16 Modernatx, Inc. Human cytomegalovirus vaccine
CA3060019A1 (en) 2017-04-19 2018-10-25 Glaxosmithkline Biologicals Sa Modified cytomegalovirus proteins and stabilized complexes
US11524069B2 (en) 2017-09-13 2022-12-13 Sanofi Pasteur Human cytomegalovirus immunogenic composition
MX2020004434A (es) * 2017-11-01 2020-08-06 Merck Sharp & Dohme Formulaciones estables de citomegalovirus.
CN108300731A (zh) * 2018-02-02 2018-07-20 暨南大学 含有人巨细胞病毒ul115基因的重组质粒、基因工程菌及其应用
KR200492821Y1 (ko) 2018-08-10 2020-12-15 인제대학교 산학협력단 의료용 튜브 고정 기구
CA3116175A1 (en) 2018-10-17 2020-04-23 Glaxosmithkline Biologicals Sa Modified cytomegalovirus proteins and stabilized complexes
US20220023416A1 (en) 2018-12-10 2022-01-27 Km Biologics Co., Ltd. Vaccine for preventing or treating congenital infection with cytomegalovirus
EP4163378A4 (en) 2020-06-09 2024-03-13 KM Biologics Co., Ltd. PENTAMER AND GB FUSION PROTEIN OF CYTOMEGALOVIRUS AND VACCINE CONTAINING THIS FUSION PROTEIN
US11406703B2 (en) 2020-08-25 2022-08-09 Modernatx, Inc. Human cytomegalovirus vaccine
KR102259156B1 (ko) 2020-09-28 2021-06-01 박나은 네트워크 환경 내 디바이스 인증 시스템 및 방법
EP4237085A1 (en) 2020-10-28 2023-09-06 Sanofi Pasteur Liposomes containing tlr4 agonist, preparation and uses thereof
WO2023223255A1 (en) 2022-05-20 2023-11-23 Glaxosmithkline Biologicals Sa Modified varicella zoster virus glycoprotein e proteins

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5244805A (en) * 1989-05-17 1993-09-14 University Of Georgia Research Foundation, Inc. Baculovirus expression vectors
WO2001044441A1 (en) * 1999-12-14 2001-06-21 Thermo Biostar, Inc. Stabilizing diluent for polypeptides and antigens
US7629160B2 (en) 2004-12-21 2009-12-08 University Of Kentucky Research Foundation Vectors and methods for enhanced cell longevity and protein expression
EP1783228A1 (en) 2005-11-08 2007-05-09 ETH Zürich Recombinant expression of multiprotein complexes using polygenes
US7704510B2 (en) * 2006-06-07 2010-04-27 The Trustees Of Princeton University Cytomegalovirus surface protein complex for use in vaccines and as a drug target
EP2614072A4 (en) * 2010-09-09 2014-03-19 Univ Virginia Commonwealth VACCINE AGAINST THE HUMAN CYTOMEGALOVIRUS
WO2012051211A2 (en) * 2010-10-11 2012-04-19 Novartis Ag Antigen delivery platforms
CA2826199A1 (en) * 2011-01-31 2012-08-09 The Trustees Of The University Of Pennsylvania Nucleic acid molecules encoding novel herpes antigens, vaccine comprising the same, and methods of use thereof
EP3508219A1 (en) * 2011-07-06 2019-07-10 GlaxoSmithKline Biologicals S.A. Self-replicating rna prime - protein boost vaccines
US9683022B2 (en) * 2012-07-06 2017-06-20 Glaxosmithkline Biologicals S.A. Complexes of cytomegalovirus proteins
KR20150076244A (ko) * 2012-10-30 2015-07-06 레드박스 게엠베하 인간 시토메갈로바이러스 감염에 대한 재조합 입자 기재 백신

Also Published As

Publication number Publication date
TW201609792A (zh) 2016-03-16
KR20170002560A (ko) 2017-01-06
EP3139953A1 (en) 2017-03-15
CA2947938A1 (en) 2015-11-12
PE20170301A1 (es) 2017-03-30
RU2016147987A (ru) 2018-06-13
AU2015257330A1 (en) 2016-11-17
BR112016025792A2 (pt) 2017-10-17
PH12016502220A1 (en) 2017-01-09
JP2017515503A (ja) 2017-06-15
IL248803A0 (en) 2017-01-31
US20150322115A1 (en) 2015-11-12
SG11201608977UA (en) 2016-11-29
CN106460010A (zh) 2017-02-22
WO2015170287A1 (en) 2015-11-12

Similar Documents

Publication Publication Date Title
PH12016502220A1 (en) Means and methods for treating cmv
JOP20200192A1 (ar) أجسام مضادة لـ tigit
EP4344741A3 (en) Aav vectors targeted to the central nervous system
HK1248759A1 (zh) 用於產生製備疫苗的病毒的方法
IL248483A0 (en) Different strains of Listeria recombinant vaccines and methods for their production
EP3009505A4 (en) Recombinant strain producing l-amino acids, constructing method therefor and method for producing l-amino acids.
EP3506939A4 (en) METHOD FOR PRODUCING A VIRUS FOR THE VACCINE PRODUCTION
MX2016016886A (es) Anticuerpos anti-axl.
EP3113800A4 (en) Enhanced production of recombinant crm197 in e. coli
EP3294450A4 (en) PROCESS FOR PRODUCING MODIFIED CLAY, MODIFIED CLAY PRODUCED AND USE THEREOF
EP3207142A4 (en) Recombinant listeria vaccine strains and methods of using the same in cancer immunotherapy
MY191539A (en) Streptococcal vaccine
TW201613893A (en) Process for the preparation of 3-(3-chloro-1H-pyrazol-1-yl)pyridine
IN2015KN00323A (es)
MX369662B (es) Granulos de harina de microalgas y proceso de preparacion de estos.
MX2017003301A (es) Producto refractario, relleno para fabricar el producto, procedimiento para fabricar el producto y uso del producto refractario.
MX2016010838A (es) Vacunas de proproteina convertasa subtilisina/kexina tipo 9 (pcsk9).
EP3106516A4 (en) Recombinant microorganism of genus escherichia with l-threonine productivity, and method for producing l-threonine using same
EP3183270A4 (en) Hiv antibody therapy as treatment substitute
PL3110756T3 (pl) Sposób otrzymywania modyfikowanej krzemionki, modyfikowana krzemionka i jej zastosowania, w szczególności do wzmacniania polimerów
MX2017008776A (es) Relleno para preparar un producto refractario, un procedimiento para preparar un producto refractario, un producto refractario, y uso de un producto refractario.
IN2014CH01391A (es)
MX2016002186A (es) Proceso para preparar dronedarona y sales de la misma.
IN2013CH05865A (es)
PH12018500339A1 (en) Lysobactin for use in the treatment of bovine mastitis